Compounded Semaglutide Legal Status by Channel
A medical spa running forty semaglutide patients a week out of a strip-mall suite in Scottsdale got a call from its 503B supplier in March 2025: bulk semaglutide vials were being discontinued…
Blog Topic
Policy & Access
The regulatory and access context around GLP-1 and GLP-3 therapies — FDA status, shortage and compounding policy, and how supply changes affect availability. Informational coverage, not legal or medical guidance.
Compounded Semaglutide Pharmacy Access During the 2025 FDA Shortage Transition
The Shortage Is Over — But the Access Problem Isn't In February 2025, the FDA officially removed semaglutide from its drug shortage database. On paper, that sounds like a win. In practice…